Newsletters
- All
- Incentives
- Jobs
- Media & Graphics
- PK & PK-PD
- R&D Insight
- Wonkish
- Y2017
- Y2018
- Y2019
- Y2020
- Y2021
- All
- Incentives
- Jobs
- Media & Graphics
- PK & PK-PD
- R&D Insight
- Wonkish
- Y2017
- Y2018
- Y2019
- Y2020
- Y2021
Workshop on TB drugs: Lessons for the antibacterial community
Dear All: I listened with interest to the 19 July 2017 FDA Workshop entitled “Development of New Tuberculosis Treatment Regimens– …
G20 declaration – Statements about action on AMR
Dear All: The G20 have released a declaration in which they specifically discuss their intent around AMR. See below a …
Lancet ID Commentary to the G20 on behalf of the DRIVE-AB Steering Committee
I am pleased to say that a commentary to the G20 on behalf of the DRIVE-AB Steering Committee has now …
Developing systemic & inhaled antibiotics for lung infections
Dear All: I missed it personally, but by all reports the session on 3 June 2017 at ASM Microbe entitled …
New European Action Plan on AMR
Dear All: An updated European One Health Action Plan on AMR was released today. See links and text excerpts below …
Delafloxacin approval / Good example of a modern label
Dear All: FDA’s approval of delafloxacin (BAXDELA) was announced on 20 June 2017 and the label can be found here. In …
FNIH’s submission to the HABP/VABP docket
Dear All: After a multi-year gestation period (my notes on this project go back to 2012!!), a comment on the …
NIAID workshop: What is a robust PK-PD package?
Dear All: The ~150 of us who gathered in Washington yesterday and today for the NIAID’s PK-PD workshop enjoyed a …
Assessing antibiotic value: Two papers on antibiotic-specific gaps in traditional Health Technology Assessments
Dear All: Among various paradoxes that surround antibiotic development, the challenge for health technology assessment (HTA) is often implied but …
Ardal et al. / Pull incentives for antibiotics – TATFAR analysis of 6 models
Dear All: The TATFAR group has a new and very helpful paper out in Clinical Infectious Diseases in which they analyze 6 …
Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance
Dear All: Along with our co-authors (Mark Goldberger, Barry Eisenstein, Roger Echols, John Tomayko, Mike Dudley, and Aaron Dane), George Talbot …
G20 Health Minister’s declaration / Calls for push, pull, avoiding price/volume mechanisms, and support of global partnerships!
Dear All: Adding to the continued forward momentum of calls for support of antibiotic R&D, this week’s meeting of the G20 Health …
New OHE report on incentives for antibiotics
Dear All: Just hitting my inbox today is this report from OHE. The paper reviews in detail the incentive proposals in the 2016 O’Neill …
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
Dear All (long note alert … there’s a lot of material below my signature): Just published today is an IDSA …
FDA AMDAC – Developing Single-Pathogen agents for P. aeruginosa and A. baumannii
Dear All (and with apologies … long note alert!): Yesterday’s AMDAC was very productive. For reference, all the materials are here and …
CARB-X funding round #1, SDRI 2017, & Antibiotic-tainted seafood
Dear All: Just in case you missed the 30 March annoucement, see at right a snapshot of the first 11 Powered …
Antimicrobial Effects of Antipyretics, a paper in AAC by Zimmerman & Curtis
Dear All: OK, I’ll say that I’m sending this around because the title was so intriguing and reminded me of the …
International Course on Antibiotics and Resistance ICARe, 11-19 Nov 2017
Dear All: FYI, see below an announcement of an 8-day intensive course in Paris in November 2017: “ICARe is designed …
IDSA’s Faces of Antimicrobial Resistance (FAOR) report
Dear All: This one appears to have been released on 7 Mar but it just crossed my desk today. In …
Useful AMR graphics: Poirel 2017 and Marston 2016
Dear All: There’s a very comprehensive review of the polymyxins by Poirel, Jayol, and Nordmann just out in Clin Micro …
